Biotop-report 2011

24

B i o T O P i c s   4 2 _

B i o T O P   R e p o r t   2 0 1 1

caprotec bioanalytics GmbH

caprotec bioanalytics GmbH has devel-

oped a ground-breaking, proprietary 

tech  nology to reduce the complexity of 

protein mixtures in a targeted and 

directed manner. 

Founded in 2006 by scientist and entre-

preneur Prof. Dr. Hubert Köster, founder of 

Sequenom Inc. and Biosyntec, caprotec 

raised approx. 9 million $ in 2007 and 5 

million $ in 2010. Caprotec is operational 

in Berlin Adlershof since the beginning 

of 2008 and currently has 30 employees. 

caprotec’s Capture Compound Mass Spec -

trometry (CCMS) Technology is based on 

multifunctional small molecules that are 

used to target, capture, and isolate pro-

teins based on their functionality. The 

company  is  commercializing  the  CCMS 

technology as kits for research applica-

tions and in the form of collaborations 

for drug development. 

In collaborations for drug development 

caprotec is using small molecule drugs 

or drug candidates to establish a profile 

of proteins that interact with the specific 

small molecule. The profile can be used 

to elucidate the mode of action of drugs 

and drug candidates and also to discover 

off-target proteins that are responsible 

for unwanted side effects, e. g. liver 

toxicity. 

Address

caprotec bioanalytics GmbH 

Volmerstraße 5

12489 Berlin · Germany

Contact

Dr. Christian Jurinke

Director, Product Management

Phone [phone]

[e-mail]

www.caprotec.com

caproKit™ for the characterization of  

staurosporine binding protein kinases

Glycotope GmbH

Glycotope has developed a unique and regu-

latory approved platform technology for the 

development and production of NBEs and 

improved second generation biopharmaceu-

ticals / BioBetters. This toolbox of human cell 

lines allows the manifold improvement of 

key clinical properties (such as activity, avail-

ability, immunogenicity) for both antibodies 

and non-Ab proteins via targeted alteration 

of the glycosylation. With excellent produc-

tion features, GlycoExpress is also the base of 

Glycotope’s current late-stage pipeline of 4 

therapeutic antibodies – two of which have 

entered the clinic in 2009 and 2010 with the 

third to follow in Q2/2011 – and a non-AB 

protein-hormone scheduled to initiate clini-

cal trials in H2/2011.

GlycoExpress

 

p

Toolbox of glycoengineered human cell 

lines

 

p

Fully human & optimized glycosylation

 

p

Highly improved bioactivity, 

bioavailability & immunogenicity

 

p

Screening and high yield production 

system

 

p

Permits new patent protection of 

products

Pipeline of GlycoOptimized Products

 

p

Proprietary NBEs & improved second 

generation BioBetter antibody and 

non-antibody products

Via Glycotope Biotechnology

 

p

GMP-Production of biologics

 

p

Fill & Finish of API and drug 

Address

Glycotope GmbH

Robert-Roessle-Strasse 10

13125 Berlin · Germany

Phone  [phone]

Fax 

[phone]

[e-mail]

www.glycotope.com

---

25

B i o T O P i c s   4 2 _

B i o T O P   R e p o r t   2 0 1 1

SILENCE Therapeutics AG is the leading 

RNAi therapeutics company in Europe. 

The Company has developed novel, pro-

prietary short interfering RNA (

siRNA) 

molecules called 

AtuRNAi and proprietary 

systemic delivery systems for siRNA.

Strong IP Position

SILENCE’s strong IP position is based on a 

broad portfolio of patents issued in the 

US, Europe and other territories.

Validating Pharma Partnerships

SILENCE has established validating part-

nerships with 

AstraZeneca ($15m upfront 

payment  &  equity,  $400m  milestone 

payments), 

Pfizer/Quark ($95m mile-

stone payments incl. upfront) & 

Dainip-

pon Sumitomo (delivery collaboration) 

and 

Novartis/Quark  ($80m  milestone 

payments incl. upfront).

Four Clinical AtuRNAi Programs

Out of 11 clinical siRNA programs world-

wide as of April 2010 there are 

4 clinical 

programs (see table) with SILENCE’s AtuR-

NAi molecules. These are SILENCE’s inter-

nal lead program 

Atu027 and three clini-

cal study programs conducted by SILENCE’s 

partners Pfizer and Quark. This underlines 

SILENCE’s leadership in the field of siRNA 

therapeutics.

Internal Lead Program

SILENCE’s internal lead program 

Atu027 

is currently in a 

Phase I clinical study 

recruiting patients with advanced gastro-

intestinal, lung and other solid cancer (21 

patients enrolled as of February 2011). 

Recent Corporate Highlights

 

p

November 10, 2010 Landmark pub-

lication in Clinical Cancer Research 

demonstrating the ability of Silence’s 

siRNA drug candidate, Atu027, to 

prevent the formation of pulmonary 

metastasis in various animal models 

of cancer metastasis.

 

p

August 19, 2010 Novartis takes an 

option from Quark Pharma (“Quark”) 

to obtain an exclusive worldwide 

license to develop and commercialise 

QPI-1002, a p53 temporary inhibi-

tor siRNA drug which incorporates 

Silence’s  AtuRNAi  technology  ($80mil-

lion milestone payments for Silence).

 

p

July 14, 2010 Extension of the 

research collaboration and license 

agreement with AstraZeneca which 

started in 2007. Silence and Astra-

Zeneca are jointly collaborating on 

the identification and optimization of 

five novel siRNA therapeutic molecules 

addressing respiratory and oncology 

indications.

 

p

May-October 2010 Issuance of various 

patents by the United States Patent 

and  Trademark  Office  and  the  Euro-

pean Patent Office.

 

p

April 21, 2010 Extension of the siRNA 

delivery collaboration with AstraZen-

eca which started in 2008. Under this 

collaboration a number of Silence’s 

proprietary lipid delivery and tar-

geting technologies are leveraged to 

develop new and enhanced delivery 

approaches for siRNAi therapeutics.

 

p

March 30, 2010 Expansion of the siRNA 

delivery collaboration with Dainippon 

Sumitomo Pharma which started in 

2009 in order to examine additional 

disease targets. 

 

p

January 5, 2010 Merger with US based 

Intradigm Corporation - The enlarged 

company now possesses multiple RNAi 

discovery, development and delivery 

technologies, an advancing internal 

and partnered product pipeline and 

a broad portfolio of intellectual prop-

erty.

SILENCE Therapeutics AG, Berlin, is listed 

through its holding company SILENCE 

Therapeutics plc, London, at the Alterna-

tive Investments Market (AIM) of the Lon-

don Stock Exchange.

Silence Therapeutics AG

Address

Silence Therapeutics AG

Robert-Rössle-Straße 10

13125 Berlin · Germany 

Contact

Thomas Christély 

Chief Executive Officer

Dr. Klaus Giese 

Chief Scientific Officer

Dr. Jörg Kaufmann

VP Research

Phone [phone]

Fax 

[phone]

www.silence-therapeutics.de

[e-mail]

Overview of AtuRNAi Programs

Products

Indications

Partners

Target

Delivery

Preclinical

Phase I

Phase II

Target Tissue/ Organ

PF-4523655 Age-related Macular Degeneration

Quark/Pfizer

RTP-801 (REDD1)

Naked siRNA

Local Delivery to the Eye

QPI-1002

Prevention of Delayed Graft Function

Quark/Novartis

p53

Naked siRNA

Systemic Delivery to the Kidney

QPI-1002

Acute Kidney Injury 

Quark

p53

Naked siRNA

Systemic Delivery to the Kidney

Atu027

Solid Tumors (anti-metastatic)

Internal

PKN3

AtuPLEX

Systemic Delivery to Tumor Endothelium

Atu111

Acute Lung Injury

Internal

Ang-2

DACC

Systemic Delivery to Lung Endothelium

Atu134

Solid Tumors 

Internal

CD31

AtuPLEX

Systemic Delivery to Tumor Endothelium

Atu150

Solid Tumors

Internal

p110

AtuPLEX

Systemic Delivery to Tumor Endothelium

---